$0.69 Earnings Per Share Expected for Balchem Co. (BCPC) This Quarter

Equities research analysts expect Balchem Co. (NASDAQ:BCPC) to report $0.69 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Balchem’s earnings. The highest EPS estimate is $0.73 and the lowest is $0.65. Balchem reported earnings per share of $0.76 during the same quarter last year, which suggests a negative year over year growth rate of 9.2%. The company is expected to announce its next quarterly earnings results before the market opens on Friday, May 3rd.

On average, analysts expect that Balchem will report full year earnings of $3.02 per share for the current financial year, with EPS estimates ranging from $2.89 to $3.15. For the next financial year, analysts forecast that the business will report earnings of $3.45 per share, with EPS estimates ranging from $3.30 to $3.60. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Balchem.

Balchem (NASDAQ:BCPC) last issued its earnings results on Thursday, February 28th. The basic materials company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.66 by $0.11. The company had revenue of $163.50 million during the quarter, compared to analyst estimates of $161.42 million. Balchem had a return on equity of 14.59% and a net margin of 12.21%. The company’s revenue was up 2.6% on a year-over-year basis.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Balchem from a “buy” rating to a “hold” rating in a research report on Tuesday, March 12th. BidaskClub lowered Balchem from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Seaport Global Securities assumed coverage on Balchem in a research report on Thursday, February 21st. They set a “neutral” rating for the company. Finally, HC Wainwright set a $101.00 price objective on Balchem and gave the company a “buy” rating in a research report on Tuesday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Balchem has an average rating of “Hold” and a consensus target price of $105.50.

NASDAQ:BCPC opened at $98.93 on Friday. Balchem has a 12-month low of $73.16 and a 12-month high of $117.79. The company has a market cap of $3.16 billion, a P/E ratio of 32.85 and a beta of 1.00. The company has a quick ratio of 1.94, a current ratio of 2.76 and a debt-to-equity ratio of 0.24.

Institutional investors have recently made changes to their positions in the business. First Hawaiian Bank raised its stake in Balchem by 68.0% during the 1st quarter. First Hawaiian Bank now owns 378 shares of the basic materials company’s stock valued at $35,000 after acquiring an additional 153 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in Balchem during the 4th quarter valued at $39,000. Pearl River Capital LLC bought a new stake in Balchem during the 4th quarter valued at $45,000. Bank of Montreal Can raised its stake in Balchem by 13.6% during the 4th quarter. Bank of Montreal Can now owns 1,926 shares of the basic materials company’s stock valued at $151,000 after acquiring an additional 231 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new stake in Balchem during the 4th quarter valued at $188,000. 87.80% of the stock is currently owned by hedge funds and other institutional investors.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Recommended Story: What is a stock buyback?

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.